66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-C000000006 | 2005/01/01 | 01/08/2005 | Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety | Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety - Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01) | IgA nephropathy in children | Lisinopril for 2 years Lisinopril+losartan for 2 years | Japanese Study group of Kidney Disease in Children | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 110 | Not selected | Japan |
2 | JPRN-C000000373 | 1998/08/01 | 01/04/2006 | Lisinopril for IgA nephropathy with focal mesangial proliferation in children | Lisinopril for IgA nephropathy with focal mesangial proliferation in children - Lisinopril for IgA nephropathy with focal mesangial proliferation in children | IgA nephropathy in children | Lisinopril for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 50 | Not selected | Japan |